{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/reducing-white-space-pursuing-achievable-efficiencies-clinical-trials#webpage",
"url": "https://www.fortrea.com/insights/reducing-white-space-pursuing-achievable-efficiencies-clinical-trials",
"name": "Reducing ‘white space’: Pursuing achievable efficiencies in clinical trials",
"description": "This Fortrea article examines how reducing white space in clinical development can significantly improve clinical trial efficiency, productivity, and execution. White space refers to periods of inactivity, operational delays, handoff gaps, and process inefficiencies that extend study timelines without adding scientific or clinical value. As development programs become increasingly complex, sponsors face growing pressure to accelerate timelines while maintaining quality and operational performance. The article explores how organizations can identify and eliminate unnecessary delays across study start-up, operational planning, site activation, enrollment activities, and trial execution to create more streamlined development pathways. By improving workflow coordination, enhancing cross-functional collaboration, reducing cycle times, and optimizing operational processes, sponsors can accelerate clinical development timelines, improve trial delivery, increase productivity, and generate clinical evidence more efficiently. The discussion highlights the importance of proactive planning, operational excellence, and continuous process improvement in reducing white space and maximizing clinical trial performance across the development lifecycle."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Reducing ‘white space’: Pursuing achievable efficiencies in clinical trials",
"item": "https://www.fortrea.com/insights/reducing-white-space-pursuing-achievable-efficiencies-clinical-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/reducing-white-space-pursuing-achievable-efficiencies-clinical-trials#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/reducing-white-space-pursuing-achievable-efficiencies-clinical-trials#webpage"
},
"headline": "Clinical Trial Efficiency: Reducing White Space to Accelerate Development Timelines and Improve Trial Execution | Fortrea Article",
"description": "This Fortrea article examines how reducing white space in clinical development can significantly improve clinical trial efficiency, productivity, and execution. White space refers to periods of inactivity, operational delays, handoff gaps, and process inefficiencies that extend study timelines without adding scientific or clinical value. As development programs become increasingly complex, sponsors face growing pressure to accelerate timelines while maintaining quality and operational performance. The article explores how organizations can identify and eliminate unnecessary delays across study start-up, operational planning, site activation, enrollment activities, and trial execution to create more streamlined development pathways. By improving workflow coordination, enhancing cross-functional collaboration, reducing cycle times, and optimizing operational processes, sponsors can accelerate clinical development timelines, improve trial delivery, increase productivity, and generate clinical evidence more efficiently. The discussion highlights the importance of proactive planning, operational excellence, and continuous process improvement in reducing white space and maximizing clinical trial performance across the development lifecycle.",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-05/reducing-white-space-clinical-trials.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-05-04",
"dateModified": "2026-05-04",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-05/reducing-white-space-clinical-trial-efficiencies.pdf",
"encodingFormat": "application/pdf"
}
}
]
}